Cash ReservesBioAge ended the first quarter with $335.1 million in cash, and the company's balance sheet is expected to fund operations through at least 2029.
Financial PerformanceThe net loss for the first quarter was better than the estimate, driven by lower-than-expected operating expenses.
Pipeline AdvancementBGE-102 continues to advance towards Phase 1 SAD data, indicating progress in the company's pipeline.